|
| 37544572 | The efficacy, safety, and tolerability of an estrogen-free oral contraceptive drospirenone 4Â mg (24/4-day regimen) in obese users. | Contraception | 2023 |
| 37863464 | Comparison of estrogenic components used for hormonal contraception. | | 2023 |
| 37084589 | Oral estradiol/micronized progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine estrogens/medroxyprogesterone acetate in real-world practice. | | 2023 |
| 37390976 | Biosynthesis of estetrol in human pregnancy: Potential pathways. | | 2023 |
| 37253139 | Satisfaction with a Segesterone Acetate and Ethinyl Estradiol Contraceptive Vaginal System Among Recent Oral Contraceptive or Hormonal Contraceptive Vaginal Ring Users. | | 2023 |
| 34582715 | Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. | J Womens Health (Larchmt) | 2022 |
| 35849455 | Double Dosing Levonorgestrel-Based Emergency Contraception for Individuals With Obesity: A Randomized Controlled Trial. | Obstet Gynecol | 2022 |
| 35956249 | Bleeding Patterns of Oral Contraceptives with a Cyclic Dosing Regimen: An Overview. | Journal of Clinical Medicine | 2022 |
| 35430238 | Evaluation of ovulation and safety outcomes in a multi-center randomized trial of three 84 day ulipristal acetate regimens. | Contraception | 2022 |
| 36075250 | Review of menopausal hormone therapy with estradiol and progesterone versus other estrogens and progestins. | Gynecological Endocrinology | 2022 |
| 35865736 | Continuation rates of two different-sized copper intrauterine devices among nulliparous women: Interim 12-month results of a single-blind, randomised, multicentre trial. | EClinicalMedicine | 2022 |
| 36257374 | Tolerability and safety of the estetrol/drospirenone combined oral contraceptive: Pooled analysis of two multicenter, open-label phase 3 trials. | Contraception | 2022 |
| 36574387 | Extended regimen of a levonorgestrel/ethinyl estradiol transdermal delivery system: Predicted serum hormone levels using a population pharmacokinetic model. | | 2022 |
| 34796470 | The Plasminogen Activator System, Glucocorticoid, and Mineralocorticoid Receptors in the Primate Endometrium During Artificial Menstrual Cycles. | Reproductive Sciences | 2022 |
| 35306927 | Profile of estetrol, a promising native estrogen for oral contraception and the relief of climacteric symptoms of menopause. | Expert Rev Clin Pharmacol | 2022 |
| 34553161 | Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis. | F S Rep | 2021 |
| 34054104 | Evaluation of endometrial progesterone receptor expression after 12 weeks of exposure to a low-dose vaginal estradiol insert. | Menopause | 2021 |
| 33785318 | Segesterone acetate serum levels with a regression model of continuous use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system. | | 2021 |
| 34000251 | Estetrol-drospirenone combination oral contraceptive: North American phase 3 efficacy and safety results. | Contraception | 2021 |
| 33564263 | Endometriosis-Related Pain Reduction During Bleeding and Nonbleeding Days in Women Treated with Elagolix. | Journal of Pain Research | 2021 |
| 33559058 | Drospirenone Effects on the Plasminogen Activator System in Immortalized Human Endometrial Endothelial Cells. | Reproductive Sciences | 2021 |
| 32702363 | Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids. | Am J Obstet Gynecol | 2021 |
| 32893694 | Uterine bleeding with hormone therapies in menopausal women: a systematic review. | Climacteric | 2020 |
| 31971678 | Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. | N Engl J Med | 2020 |
| 31913228 | Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR). | Menopause | 2020 |
| 31650182 | Elagolix Suppresses Ovulation in a Dose-Dependent Manner: Results From a 3-Month, Randomized Study in Ovulatory Women. | Journal of Clinical Endocrinology and Metabolism | 2020 |
| 32416145 | Dose-finding study of a 90-day contraceptive vaginal ring releasing estradiol and segesterone acetate. | Contraception | 2020 |
| 32107942 | A pilot study: estradiol/progesterone effect on cervico-vaginal cytokines in premenopause and postmenopause. | Climacteric | 2020 |
| 32459423 | Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. | Obstet Gynecol | 2020 |
| 32550535 | A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen. | Contracept X | 2020 |
| 33294846 | Elagolix in the treatment of endometriosis: impact beyond pain symptoms. | | 2020 |
| 32576803 | Ospemifene: less venous thrombosis than other selective estrogen receptor modulators in postmenopausal women with vulvo vaginal atrophy. | Menopause | 2020 |
| 31381878 | Comparison of self-reported female condom failure and biomarker-confirmed semen exposure. | Contraception | 2019 |
| 31526199 | Ospemifene for the treatment of menopausal vaginal dryness, a symptom of the genitourinary syndrome of menopause. | | 2019 |
| 31282768 | A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause. | Expert Review of Clinical Pharmacology | 2019 |
| 31231065 | Efficacy of the 1-year (13-cycle) segesterone acetate and ethinylestradiol contraceptive vaginal system: results of two multicentre, open-label, single-arm, phase 3 trials. | Lancet Global Health,The | 2019 |
| 30694917 | Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness: a phase 3, randomized, double-blind, placebo-controlled, multicenter trial. | Menopause | 2019 |
| 30862193 | TX-004HR clinically improves symptoms of vulvar and vaginal atrophy in postmenopausal women. | Climacteric | 2019 |
| 29406209 | Retraction notice to Doxycycline Alters the Expression of Matrix Metalloproteases in the Endometrial Cells Exposed to Ovarian Steroids and Pro-inflammatory Cytokine JRI 73/2 (April 2017);118-129. | Journal of Reproductive Immunology | 2018 |
| 28926514 | A randomized, multicenter, double-blind study to evaluate the safety and efficacy of estradiol vaginal cream 0.003% in postmenopausal women with dyspareunia as the most bothersome symptom. | Menopause | 2018 |
| 30358731 | Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. | Menopause | 2018 |
| 29889764 | Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies. | Obstetrics and Gynecology | 2018 |
| 29889748 | A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial. | Obstetrics and Gynecology | 2018 |
| 30303923 | Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial. | Obstetrics and Gynecology | 2018 |
| 29870471 | The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review. | Menopause | 2018 |
| 30238814 | Estradiol vaginal inserts (4⿿µg and 10⿿µg) for treating moderate to severe vulvar and vaginal atrophy: a review of phase 3 safety, efficacy and pharmacokinetic data. | Current Medical Research and Opinion | 2018 |
| 29944639 | To the Editor. | Menopause | 2018 |
| 29271266 | Human vaginal pH and microbiota: an update. | Gynecological Endocrinology | 2018 |
| 29509598 | Vaginal pH: a simple assessment highly correlated with vaginal morphology and symptoms in postmenopausal women. | Menopause | 2018 |
| 29409834 | Continuous dosing of a novel contraceptive vaginal ring releasing Nestorone® and estradiol: pharmacokinetics from a dose-finding study. | Contraception | 2018 |